Clinical Trials Market Size, Share, Growth Analysis, By Therapeutic Area (Oncology, Central Nervous System (CNS)), By Phase (Phase 1, Phase 2), By Study Design (Interventional, Observational), By Stakeholder, By Region - Industry Forecast 2026-2033

The global clinical trials market is forecast to grow at a CAGR of 6.5% between 2025-2032, going from USD 56.58 billion in 2024 to USD 93.65 billion in 2032.

Global clinical trials are being impacted by regulatory complexities, high costs of trials, limited resources, and bureaucracy regarding multinational compliance. These challenges are having a substantial impact on global clinical trials, particularly for smaller companies that are experiencing delays and access to patients due to stringent documentation and infrastructure requirements.

Oncology is the dominant therapeutic area in the clinical trials market with a wave of cancer drug approvals, advances in targeted therapies, and a growing funding environment. Neurology ranks second in clinical trials, driven by increasing cases of CNS diseases, most significantly Alzheimer's and Parkinson's disease.

Oncology and rare disease trials are helping fuel overall market growth by establishing demand for targeted therapies with additional FDA approvals, instilling confidence in funding on a national level and creating necessary funding globally and around patient-centric development of new drugs.

Precision medicine is changing trial design by allowing development of therapy that can specifically target a patient based on genetic components (molecularly targeted therapy) for instance. The concrete illustration of precision medicine is by success in oncology and in rare diseases, however the approach ultimately creates better outcomes for patients and improves the clinical path.

AI and machine learning support clinical trials with a number of different optimization strategies in relation to clinical trials, including buttressing patient recruitment; predicting likely outcomes; recognizing early adverse effects; and speeding analysis of data when the trial is complete. All these strategies yield efficiency gains towards the clinical trial process, and improve decision-making.

Wearable devices and remote monitoring in decentralized trials can increase participation due to prospective trial participants avoiding the travel burden (time and cost) of participating in a trial. Additionally, wearable and remote monitoring permits real-time data collection, ultimately increasing retention and collaboration for participants through flexibility.

Regulatory authorities (macro) for clinical trials in the USA and Canada are the FDA and Health Canada respectively. The EMA in Europe, and NMPA in China, and CDSCO (Central Drugs Standard Organization) in India regulate trials in their respective countries, making up the key regulatory authorities internationally. Regulatory authorities are responsible for ensuring trial safety, reducing approval timelines and enhancing innovation through trial design in their regions.

Considerations for practices involved synthesis of real-world data and the use of optimal study design, to include decentralized type trial designs, and to provide improved site support (such the NIH's Virtual Clinical Trials Office) to increase accessibility and efficiency to RWE.

RWD helps support clinical trials by providing better data quality, and opportunities to leverage improved adaptive designs, or analysis of patient outcomes. In particular, RWD supports personalized care, especially in the U.K. and U.S., where RWD is gaining more traction towards the idea of personalized care.